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Cellular senescence is a form of adaptive cellular physiology
associated with aging. Cellular senescence causes a proinflamma-
tory cellular phenotype that impairs tissue regeneration, has been
linked to stress, and is implicated in several human neurodegen-
erative diseases. We had previously determined that neural pro-
genitor cells (NPCs) derived from induced pluripotent stem cell
(iPSC) lines from patients with primary progressive multiple
sclerosis (PPMS) failed to promote oligodendrocyte progenitor cell
(OPC) maturation, whereas NPCs from age-matched control cell
lines did so efficiently. Herein, we report that expression of
hallmarks of cellular senescence were identified in SOX2+ progeni-
tor cells within white matter lesions of human progressiveMS (PMS)
autopsy brain tissues and iPS-derived NPCs from patients with
PPMS. Expression of cellular senescence genes in PPMS NPCs was
found to be reversible by treatment with rapamycin, which then
enhanced PPMS NPC support for oligodendrocyte (OL) differentia-
tion. A proteomic analysis of the PPMS NPC secretome identified
high-mobility group box-1 (HMGB1), which was found to be a
senescence-associated inhibitor of OL differentiation. Transcriptome
analysis of OPCs revealed that senescent NPCs induced expression
of epigenetic regulators mediated by extracellular HMGB1. Lastly,
we determined that progenitor cells are a source of elevated HMGB1 in
human white matter lesions. Based on these data, we conclude that
cellular senescence contributes to altered progenitor cell functions in
demyelinated lesions in MS. Moreover, these data implicate cellular
aging and senescence as a process that contributes to remyelination
failure in PMS, which may impact how this disease is modeled and
inform development of future myelin regeneration strategies.
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Cellular senescence is a component of the aging process that isincreasingly recognized as an important pathophysiological
mechanism associated with a variety of neurodegenerative hu-
man diseases (1, 2). Cellular senescence is distinct from cellular
quiescence in that senescent cells develop a unique level of cellular
activity that often exerts a proinflammatory paracrine effect on
surrounding cells that can impair or alter tissue function, termed
the senescence-associated secretory phenotype (SASP) (3, 4).
Cellular senescence is linked with increased activity of mammalian
target of rapamycin (mTOR) (5). Rapamycin has been found to
decrease the production of the SASP through inhibition of mTORC1
(4), which has enabled studies on cellular plasticity under cellular
senescence and the contribution of SASP factors to tissue and
organ function. One notable influence of cellular senescence is on
stem cells, where senescence has been shown to reduce trophic
support and lessen regenerative capacity, which can contribute to
impaired healing and tissue atrophy in aging and disease (6–8).
Progressive multiple sclerosis (PMS), which can develop either
as primary (with no or minimal identified relapses) or secondary
(with previous and sometimes ongoing relapses) progressive
forms, represents the phase of MS where there is accrual of ir-
reversible neurological disability. The unabating disability in
PMS is attributed to chronic CNS demyelination and neuro-
degeneration with minimal remyelination (9). Promoting brain
repair represents a potential strategy to restore neurological
function in patients with PMS (10). However, the success of
potential remyelinating therapies relies on endogenous oligo-
dendrocyte progenitor cells (OPCs) to differentiate into myeli-
nating oligodendrocytes (OLs) (11–15). Therefore, understanding
what limits the potential of endogenous OPCs for remyelination will
be required to realize remyelination as a therapeutic opportunity
for regeneration.
Studies analyzing white matter lesion pathology in PMS brain
tissues have identified immature, premyelinating oligodendroglia
in association with progenitor cells (16). Endogenous and trans-
planted progenitor cells have been found to be capable of secreting
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factors that are antiinflammatory and support remyelination (17–
20). Therefore, both of these cell types could be viewed as capable
of promoting regeneration; however, OPC differentiation in vivo is
limited and mostly arrested, resulting in chronic demyelination (21–
24). We have recently identified that neural progenitor cells (NPCs)
differentiated from induced pluripotent stem cells (iPSCs) derived
from patients with primary PMS (PPMS) were less able to provide
neuroprotection to myelin injury or support OPC differentiation in
vitro (25). Importantly, OPCs differentiated from iPSC lines of
patients with PPMS are equally capable of maturing into myelin-
forming OLs (26), demonstrating that OPCs in this disease have
potential that may be limited by a disease phenotype in NPCs.
In this study, we report evidence for cellular senescence in
progenitor cells in PMS and provide functional evidence that this
is a reversible process responsible for limiting OL maturation.
These data suggest that while MS is not a disease of aging, at the
cellular level, it may be an aging-related disease.
Materials and Methods
Human Tissue Immunohistochemistry. Unfixed frozen postmortem tissue was
provided by the UK Multiple Sclerosis Tissue Bank via a UK prospective donor
scheme with full ethical approval (MREC/02/2/39) and the MRC Sudden
Death Brain Bank (ethical approval LREC16/ES/0084) (SI Appendix, Table S1).
Colorimetric staining was used to detect labeling in human tissue. Ten-
micrometer sections were fixed in 4% paraformaldehyde (PFA), and anti-
gen retrieval was performed by microwaving sections in Vector H-3300
antigen unmasking solution (Vector Laboratories). Slides were blocked
with Bloxall blocking solution (Vector Laboratories), and further blocking
was then performed with 2.5% horse serum (Vector Laboratories). Sections
were incubated with the primary antibody high-mobility group box-1
(HMGB1; 1:500 mouse; BioLegend) or p16Ink4a (1:500 mouse; Thermo
Fisher Scientific) in antibody diluent (Spring Bioscience, Abcam) overnight at
4 °C. Sections were incubated with Impress HRP anti-mouse and then col-
orized with 3,3′-diaminobenzidine (DAB; Vector Laboratories). Sections were
washed and blocked in 2.5% horse serum and then incubated with anti-
bodies against SOX2 (1:500 rabbit; Reprocell) overnight at 4 °C. Sections
were incubated with Impress AP anti-rabbit, colorized with Vector Blue al-
kaline phosphatase, and then mounted in Fluoromount-G (Southern Biotech).
Sections were imaged on a Zeiss Axio Scan.Z1 microscope and processed using
Qupath software (27). Four areas measuring 0.37 mm2 each were counted
within the demyelinated lesion, remyelinated lesion, and normal-appearing
white matter (NAWM) in MS tissue and white matter of control tissue.
iPSC and NPC Culture Derivation. The iPSCs and NPCs were generated as
described previously (25), and iPSC lines from the laboratory of one of the
authors (V.F.) were derived as described previously (26) (SI Appendix, Table
S2). Cell colonies were passaged manually when needed, and NPC passage
number was kept consistent between lines for all experiments described.
Isolation of Rat OPCs and Treatment with NPC Conditioned Media. OPCs were
obtained from the cerebral cortices of neonatal rat pups (postnatal day 0–2),
and were plated on poly-L-ornithine–coated coverslips, as previously de-
scribed (28). OPCs were cultured in varying conditioned media (CM) for 48 h.
CM were taken from the NPCs after 48 h on 80% confluent cells, at least 4 d
after passage, immediately spun down to remove debris, and then frozen
at −80 °C. The CM experiments were performed in quadruplicate technical
replicates and repeated in triplicate using separately developed cultures (i.e.,
unique biological replicates). For the HMGB1 blocking experiments, CM were
collected and then incubated with 1 μg/mL function blocking α-HMGB1
antibody (BioLegend) or the appropriate isotype control (IgG) for 1 h at
37 °C on a shaker. The treated CM were then applied to OPCs for 48 h, and
differentiation was assayed. For recombinant HMGB1 treatment, OPCs were
grown in differentiation media [neurobasal media (Thermo Fisher Scientific),
2% B27, 2 mM L-glutamine, and 10 ng/mL T3] and treated with recombinant
human HMGB1 (R&D Systems) every 24 h for 48 h, for a total of two doses.
Doses consisting of 0.5, 5, 50, 500, and 5,000 ng/mL OPCs were then fixed, and
differentiation was assayed. OLs on coverslips were fixed and stained for
OLIG2 (1:500; Millipore) and myelin basic protein (MBP; 1:500; Millipore). For
all experiments, five fields of view at a magnification of 20× using identical
image capture settings were assessed by an experimenter blinded to treat-
ments (Olympus IX71, CellSens Software; Olympus). For analysis of OPC dif-
ferentiation, all OLIG2+ cells and MBP+ cells were counted and the percentage
of MBP+ cells was calculated. Data are represented as the percentage of
MBP+/OLIG2+ cells relative to the control condition set to 100%.
NPC Treatments. NPCs were treated with rapamycin (12.5 nM, daily for 48 h)
once cells became 80% confluent. After treatment, CM were collected, and
cells were collected in TriReagent (Millipore Sigma) for RNA isolation or
radioimmunoprecipitation assay (RIPA) buffer for protein isolation, or were
fixed (4% PFA) for immunocytochemistry.
Immunocytochemistry. NPCs were plated on laminin-coated coverslips (50 μg/mL;
Sigma–Aldrich) and fixed using 4% PFA. Following fixation, they were per-
meabilized using Triton X-100 (0.5%; Millipore Sigma) and blocked with
10% normal goat serum (Thermo Fisher Scientific). Cells were then stained
using the following primary antibodies overnight: p16Ink4a (1:500; Thermo
Fisher Scientific) and SOX2 (1:250; Stemgent). Appropriate secondary anti-
bodies were then applied.
Quantitative Real-Time PCR. Total RNA was isolated from NPCs plated on
laminin as described previously (29), and converted into cDNA via reverse
transcription (iScript cDNA synthesis kit; BioRad), according to the manu-
facturer’s protocol. Synthesized cDNA samples were amplified for quanti-
tative real-time PCR using primer pairs for human p16Ink4a [forward (For): 5′
GAAGGTCCCTCAGACATCCCC 3′, reverse (Rev): 5′ CCCTGTAGGACCTTCGGT-
GAC 3′], human p53 (For: 5′ CCCCTCCTGGCCCCTGTCATCTTC 3′, Rev: 5′
GCAGCGCCTCACAACCTCCGTCAT 3′), human HMGB1 (For: 5′ ACATC-
CAAAATCTTGATCAGTTA 3′, Rev: 5′ AGGACAGACTTTCAAAATGTTT 3′), and
human β-actin (For: 5′ GGACTTCGAGCAAGAGATGG 3′, Rev: 5′ AGCACT-
GTGTTGGCGTACAG 3′) using SsoAdvanced Universal SYBR Green Supermix
(BioRad) according to the manufacturer’s protocol. The PCR cycle conditions
were one cycle at 95 °C for 2 min, 40 cycles of 95 °C for 5 s, and 40 cycles at
60 °C for 30 s run on a BioRad CFX96 Touch Real-Time PCR Detection System.
Relative expression of mRNA was calculated relative to β-actin using com-
parative cycle threshold analysis.
Senescence β-Gal Staining. Human NPCs, derived from iPSCs, were plated onto
laminin-coated cover glass at equal densities (2 million cells per 35-mm well),
and β-gal staining was performed according to the manufacturer’s instruc-
tions (Cell Signaling Technology). Images were captured at a magnification
of 10× using identical phase contrast settings (Olympus IX71, CellSens Soft-
ware; Olympus). The method for quantifying senescence-associated (SA)–
β-gal is provided in SI Appendix, Fig. S5.
Immunoblots. Cells were lysed in RIPA buffer, protein content was determined
by bicinchoninic acid assay (BCA), and 20 μg of protein was separated by
electrophoresis and transferred to nitrocellulose membranes. Membranes
were blocked in Tris-buffered saline (1% Tween-20) (TBST) + 5% BSA, in-
cubated overnight with primary antibodies [phospho-mTOR (Ser2448; Cell
Signaling Technology) and GAPDH (Cell Signaling)], washed in TBST, and in-
cubated with the appropriate HRP-conjugated secondary antibody for an
hour. Proteins were visualized by chemiluminescence.
Mass Spectrometry. CM from iPS-derived NPCs from either nondisease control,
PPMS, or PPMS lines treated with rapamycin were collected and sent to the
Mass Spectrometry and Proteomics Keck Laboratory at Yale University, where
liquid chromatography (LC)-tandem mass spectrometry analysis was per-
formed on a Thermo Scientific Q Exactive Plus with a Waters nanoACQUITY
UPLC system, using a Waters Symmetry C18 180-μm × 20-mm trap column
and an ACQUITY UPLC Peptide Separation Technology [ethyline bridged
hybrid (BEH)] C18 nanoACQUITY 75-μm × 250-mm (37 °C) 1.7-μm column for
peptide separation. Trapping was done at 5 μL·min−1 with 97% buffer A
(100% water, 0.1% formic acid) for 3 min. Peptide separation was per-
formed at 330 nL·min−1 with buffer A (100% water, 0.1% formic acid) and
buffer B (100% acetonitrile, 0.1% formic acid). A linear gradient (90 min)
was run with 3% buffer B at initial conditions, 5% buffer B at 1 min, 35%
buffer B at 50 min, 50% buffer B at 60 min, 90% buffer B at 65–70 min, and
back to initial conditions at 71 min. Mass spectrometry was acquired in
profile mode over the range of 300–1,700 m/z, using one microscan, a res-
olution of 70,000, an automatic gain control (AGC) target of 3E6, and a full
maximum ion time of 45 ms. Tandem mass spectrometry was acquired in
centroid mode using one microscan, a resolution of 17,500, an AGC target of
1E5, a full maximum ion time of 100 ms, an isolation window of 1.7 m/z,
normalized collision energy of 28, and a scan range of 200–2,000 m/z. Up to
20 tandem mass spectra were collected per MS scan on species with an in-
tensity threshold of 2 × 104, using charge states +2 through +6, where
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peptide match was preferred and dynamic exclusion was set to 20 s. Data
were viewed using Scaffold Viewer (Proteome Software). Analysis of protein
lists was performed using the DAVID (Database for Annotation, Visualiza-
tion, and Integrated Discovery) bioinformatics database (30, 31), and the
percentage of proteins from the varying media associated with disease was
analyzed using the Genetic Association Database disease class. Percentages
shown in the pie graph are the percentage of proteins involved in that
disease category over total proteins (Fig. 3B). A proteomics dataset is pro-
vided (Dataset S1). The mass spectrometry proteomics data have been de-
posited to the ProteomeXchange Consortium via the PRIDE (32) partner
repository with dataset ID PXD013060.
RNA Sequencing. OPCs were plated out and treated with NPC CM from
control, PPMS, and PPMS + α-HMGB1 CM as described above. After 48 h, the
OPCs were collected in TRIzol, and RNA was isolated as described previously
(29). RNA was given to The Jackson Laboratory, where 1 μg of total RNA was
processed using the TruSeq RNA Library Preparation Kit v2 (RS-122-2001;
Illumina) according to the manufacturer’s instructions. The protocol starts
from using oligo-dT attached magnetic beads to purify the poly-A contain-
ing mRNA molecules. The purified mRNA was fragmented and reversed to
first-strand cDNA. Then, second-strand cDNA was synthesized. After end
repair and after a single “A” nucleotide was added to the 3′ ends, cDNA was
ligated to its indexing adapter. Four cycles of PCR were used to enrich the
adapter ligated DNA fragments. Following bead purification, libraries were
quantified and equally pooled together. The pooled libraries were se-
quenced on an Illumina HiSeq 4000 platform using a 75-bp end protocol and
sequenced to a depth of up to 40 million reads per library. The RNA-
sequencing (RNA-seq) samples were processed using the in-house pipeline
at The Jackson Laboratory. The reference for rat (version 6.0.91) was
obtained from Ensemble. Alignment estimation of gene expression levels
using the EM algorithm for single-ended and paired-end read data was
performed using the RSEM package (version 1.3.0); default settings were
used for alignment. Data quality control (QC) was performed using Picard
(version 1.95) and qualimap (version 2.2.1). The qualimap output was uti-
lized to examine the alignment data and to detect potential biases in
mapping data; this was computed using two analysis types: (i) BAMQC and
(ii) RNA-seq QC within the tool. BAMQC provided basic alignment statistics
[e.g., coverage, guanine-cytosine (GC) content]. RNA-seq QC provided QC
metrics, bias estimations, transcript coverage, and 5′–3′ bias computation.
Analyses of aligned reads were performed using the edgeR (v3.30.7) and
Biobase (2.38.0) packages in R (v3.4.3). Following normalization, read counts
were filtered to include genes with counts per million greater than 1 in at
least two samples. The quantile-adjusted conditional maximum likelihood
method was used to determine differentially expressed genes between li-
braries as follows: (i) control and PPMS, (ii) control and PPMS + α-HMGB1,
and (iii) PPMS and PPMS + α-HMGB1. Genes with false discovery rates
(FDRs) < 0.05 were sorted by gene ontology using Gene Ontology Consor-
tium and PANTHER analysis to get varying clusters, including myelin, oxi-
dative stress, epigenetics, and senescence. All heatmaps were made in
RStudio (V. 1.1.419) using the packages “gplots” and “RColorBrewer,” and
were organized by gene log fold change. An RNA-seq dataset is provided
(Dataset S2).
Statistical Analysis. Data were analyzed by Student’s t test or one-way
ANOVA with Tukey’s multiple comparison test, where appropriate and as
indicated, using GraphPad Prism version 7 for Mac OS X (GraphPad Software;
https://www.graphpad.com). Differences were considered significant when
P < 0.05. Data are presented as mean ± SEM.
Results
Cellular Senescence Is Present in Progenitor Cells of PMS Brain Tissue
and in iPS-Derived NPCs from Patients with PPMS.Age is recognized
as an irreversible process that limits tissue regeneration and
impairs CNS remyelination (33, 34). We hypothesized that the
process of cellular aging called cellular senescence may con-
tribute to differences in support for myelination previously
reported by NPCs derived from PPMS and nondisease control
iPSC lines (25). Human autopsy brain tissue samples from pa-
tients confirmed to have PMS and age-matched controls were
immunostained for the progenitor cell marker SOX2, along with
p16Ink4a, a cyclin-dependent kinase inhibitor and an established
marker of senescence (35). Within the demyelinated lesions of
the PMS brain, we found there to be a significant increase in the
number of SOX2+ progenitor cells in white matter lesions, com-
pared with either NAWM or white matter of control brain sam-
ples, and a decrease in SOX2+ progenitor cells in the remyelinated
lesions (Fig. 1 A and B and SI Appendix, Table S1). We also
confirmed that the p16Ink4a detected was not an artifact of DAB
staining (SI Appendix, Fig. S1) and established the presence of
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Fig. 1. Senescent markers identify progenitor cells within demyelinated
lesions of human PMS brain tissue and in iPS-derived NPCs from patients
with PPMS. (A) Human brain tissue from the frontal lobe, subcortical white
matter was stained for SOX2 (blue, progenitor marker) and p16Ink4a (red,
senescence marker) in neurospecimens from controls and PMS patients. The
representative control image is SD 22/16 (SI Appendix, Table S1), and rep-
resentative MS NAWM and MS demyelinated (DM) lesion images are from
MS 640 (SI Appendix, Table S1). (Scale bars, 20 μm.) (B) Increase in total
number of SOX2+ cells in the MS DM lesion compared with control and MS
NAWM area and control tissue (*P < 0.05, **P < 0.01; ANOVA with Tukey’s
multiple comparison test). Individual points are individual patients, and
matching colors between MS lesion samples represent the same patient.
Color coding for patient samples is presented in SI Appendix, Table S1. RM,
remyelinated. (C) Percentage of SOX2+ NPCs colabeling with p16Ink4a in MS
NAWM, MS DM lesion, and MS RM lesion areas in the same patients iden-
tified by color coding (P = 0.4430, one-way ANOVA). (D) SA–β-gal staining in
control (Cntl) NPC and PPMS iPS-derived NPC cultures in vitro revealed LacZ
activity (shown in blue) in PPMS NPC cultures. Figures show representative
lines 3.1 and 3 (SI Appendix, Table S2). (Scale bar, 400 μm.) (E) Quantification
of SA–β-gal staining in Cntl and PPMS NPCs shows an increase in LacZ in
PPMS cultures (**P < 0.01, t test). Staining was performed and quantified in
triplicate in each NPC line. (F and G) p16Ink4a and p53 mRNA expression by
qPCR in Cntl NPC and PPMS NPC cultures revealed a significant increase in
p16Ink4a and p53 mRNA levels in PPMS NPCs (***P < 0.001, **P < 0.0022;
unpaired t tests). All qPCR data were normalized to Cntl NPC lines. Each data
point represents an individual stem cell line and/or clone performed in
triplicate.
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SOX2+ cells in both control white matter and demyelinated MS
tissue using BaseScope mRNA detection (SI Appendix, Fig. S2).
This increase in progenitor cells within demyelinated lesions was
consistent with previously reported observations (16). However,
when colabeled with p16Ink4a, we identified that the majority of
SOX2+ progenitor cells within the demyelinated lesion area of the
PMS brain expressed this senescence marker (Fig. 1 A and C). To
further support these data, we performed confocal immunofluo-
rescence and found cells expressing both SOX2+ and p16ink4a
within MS lesion tissue [SI Appendix, Fig. S3 and accompanying Z-
stack Graphics Interchange Format (GIF) (Movie S1)]. These data
indicated the presence of elevated cellular senescence in pro-
genitor cells in the PMS brain.
To further characterize cellular senescence in the PMS pro-
genitor cells, and to interrogate a functional role for this aging
process in human progenitor cells, we differentiated NPCs from
iPSC lines of patients with PPMS and age-matched control do-
nors (SI Appendix, Table S2). We found that control and PPMS
iPS-derived NPCs exhibited equivalent differentiation into
NPCs, and did not differ based on the iPSC of origin (SI Ap-
pendix, Fig. S4). Next, we determined whether expression of the
lysosomal enzyme β-gal, also a marker of cellular senescence
(36), was present in the iPS-derived NPCs. Elevated activity of
SA–β-gal in PPMS NPCs was observed, while little to no activity
was detected in any NPCs from nondisease control iPSC lines
(Fig. 1 D and E and SI Appendix, Fig. S4, demonstration of
quantification methodology). We then examined by quantitative
PCR (qPCR) the expression of p16Ink4a and p53, which are both
known markers of cellular senescence (37–39). Significantly
higher mRNA expression of p16Ink4a and p53 was measured in
PPMS NPCs compared with control NPCs (Fig. 1 F and G).
Since cellular senescence is known to be associated with cell
cycle arrest (40), we performed cell cycle analysis and examined
the proportion of NPCs in G0/G1, G2/M, and S phases. We
found no significant differences between control and PPMS
NPCs in terms of cell cycle, indicating that evidence of senes-
cence in PPMS NPCs was not accountable to replicative senes-
cence (SI Appendix, Fig. S5B). Collectively, these independent
markers of cellular senescence identified increased senescence in
PPMS NPCs compared with the age-matched control NPCs,
even though the chronological age of the human donors in both
groups did not differ (SI Appendix, Table S2). We also consid-
ered whether these changes may relate to differentiation toward
NPCs. To test this, we assayed p16Ink4a expression in the un-
differentiated iPSC state. Interestingly, we found no differences
in p16Ink4a mRNA expression among the different cell lines (SI
Appendix, Fig. S6), suggesting that these early-passage iPSC lines
adopted a cellular senescent phenotype only when differentiated
to NPCs.
Reversal of Cellular Senescence in NPCs Promotes OPC Maturation.
The identification of cellular senescence markers in progenitor
cells of PMS tissue and in PPMS NPCs led us to hypothesize that
this intrinsic process may underlie the failure of PPMS NPCs to
support OPC maturation as we had previously reported (25).
Given that a senescent phenotype also contributes to a secretory
phenotype, we selected to affect cellular senescence in PPMS
NPCs using rapamycin, which would also block the SASP. We
first confirmed that treatment of PPMS NPCs with rapamycin
(12.5 nM, 48 h) resulted in decreased mTOR phosphorylation in
PPMS NPCs, as determined by Western blotting (Fig. 2 A and
B). We then assayed expression of senescence markers. This
brief rapamycin treatment of PPMS NPCs decreased p16Ink4a
mRNA and protein expression assayed by qPCR and immuno-
cytochemistry, respectively (Fig. 2 C and D). SA–β-gal staining
also decreased in intensity to that observed in nondiseased control
NPCs following rapamycin treatment (Fig. 2E). These findings
demonstrated that rapamycin effectively reduced expression
of the key cellular senescence markers p16Ink4a and SA–β-gal in
PPMS NPCs.
We next determined whether rapamycin affected the potential
for PPMS NPCs to support OPC differentiation. To test this, we
collected CM from PPMS NPC cultures that had been treated
with either rapamycin or vehicle, and these media were separately
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Fig. 2. Cellular senescence phenotype in iPS-derived NPCs from patients
with PPMS is reversed by treatment with rapamycin. (A) Western blot of
protein lysates from control (Cntl) NPCs, PPMS NPCs, and PPMS NPCs treated
with rapamycin (Rapa) for 48 h probed for phospho-mTOR (pmTOR;
Ser2481), mTOR, and GAPDH. (B) Densitometry of pmTOR over mTOR shows
a significant decrease in pmTOR after Rapa treatment (*P < 0.05, t test). (C)
p16Ink4a and SOX2 staining in Cntl, PPMS, and PPMS NPCs treated with Rapa
shows a decrease in p16Ink4a protein expression in the PPMS NPCs. The figure
shows representative lines 1 and 1.1. (Scale bar, 50 μm.) (D) Decrease in PPMS
NPC p16Ink4a mRNA expression after treatment with Rapa for 48 h [PPMS vs.
PPMS + Rapa (****P < 0.0001), Cntl vs. PPMS (***P < 0.001), Cntl vs. PPMS +
Rapa (P = 0.6418); ANOVA with Tukey’s multiple comparison test]. Data are
normalized to Cntl NPC lines. Each data point represents an individual stem
cell line and/or clone performed in triplicate. (E) Quantification of SA–β-gal
staining in Cntl NPCs, PPMS NPCs, and Rapa-treated PPMS NPCs [PPMS vs.
PPMS + Rapa (*P < 0.05), Cntl vs. PPMS (*P < 0.05), Cntl vs. PPMS + Rapa (P =
0.7483); ANOVA with Tukey’s multiple comparison test]. Staining was per-
formed and quantified in triplicate in each NPC line and/or clone. ns, not
significant. (F) Quantitative analysis of OL maturation (MBP+/OLIG2+)
resulting from culture of OPCs in various CM, as indicated, after 48 h of
treatment. CM were collected from Cntl NPCs, Cntl NPCs + Rapa, PPMS NPCs,
and PPMS NPCs + Rapa. All conditions were quantified relative to differ-
entiation under N2/B27 (standardized Cntl) non-CM set to 100% [Cntl CM vs.
PPMS CM (*P < 0.05), Cntl CM vs. PPMS + Rapa CM (P = 0.9974)]; ANOVA
with Tukey’s multiple comparison test]. All conditions were performed in
triplicate with the varying NPC lines. (G) Quantification of total OLIG2+ cells
under each treatment condition showing equivalent densities of cells under
all conditions, indicating that differences in differentiation were not a result
of cellular proliferation or cell death. Values are mean ± SEM (P = 0.5030;
ANOVA).
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applied to OPC cultures. Consistent with our previous work (25),
we found that CM from PPMS NPCs did not promote the dif-
ferentiation of OPCs, as assayed by MBP expression, compared
with control NPC CM, and did not alter OPC numbers (Fig. 2F).
In contrast, OPCs grown in CM from rapamycin-treated PPMS
NPCs were found to differentiate into MBP+ OLs at a rate
comparable to OPCs grown under control NPC CM conditions
(Fig. 2F). Treatment of the control NPCs with rapamycin did not
negatively affect their ability to promote OL maturation via CM
(Fig. 2F). This effect of rapamycin on human NPCs contrasts with
previous studies examining the direct effects of mTOR signaling
on OPCs (41, 42), indicating that rapamycin was not transferred to
the OPCs in the CM. However, to verify that this was the case, we
also tested whether carryover of rapamycin could have in-
dependently promoted OPC differentiation in OPCs grown in
PPMS CM. OPCs were treated directly with the same concen-
tration of rapamycin used to treat the NPCs (12.5 nM), and we
found no increase in differentiation (SI Appendix, Fig. S7). This
was consistent with previous work that had shown direct treatment
of OPCs with rapamycin may actually inhibit OPC differentiation
(43). Importantly, treatment of OPCs under any of these media
conditions tested did not result in differences in cell death, as the
number of OLIG2+ cells did not differ among any of the experi-
mental treatment conditions (Fig. 2G). Hence, reversing senes-
cence in PPMS NPCs using rapamycin was not only found to
provide a change in senescence marker expression but to result in
a significant improvement in PPMS NPC function reflected by
enhanced OPC differentiation.
Proteomic Analysis of NPC Secretome Identified HMGB1 as a Potent
Inhibitor of OL Differentiation. To identify what factor(s) in the
NPC CM were responsible for impaired OPC differentiation, we
performed LC-tandem mass spectrometry on the CM from
control NPCs, PPMS NPCs, and rapamycin-treated PPMS NPCs
to identify and compare peptides from each of these conditions
(Dataset S1). For this analysis, we exploited the heterogeneity of
the human donors to provide higher stringency to the compari-
sons, where only factors found in all samples in a treatment
group were considered valid targets. From these proteomic
analyses, we identified several factors uniquely expressed by
PPMS NPCs. Many of these peptides represented secreted
proteins previously known to be associated with cellular senes-
cence, including heat shock proteins 90 and 60, DJ-1, and
HMGB1 (Fig. 3A). Importantly, these factors were not found to
be produced by either the control NPCs or when PPMS NPCs
had been treated with rapamycin (Fig. 3A). Ontology analysis of
the identified peptides using the DAVID bioinformatics data-
base revealed that 14.5% of proteins secreted by PPMS NPCs
were associated with “aging.” This aging profile was reduced to
only 4.8% of peptides identified from PPMS NPCs that had been
treated with rapamycin, which represents a decrease of 67%. No
aging ontology was identified from the secretome of control NPCs
(Fig. 3B). These findings lend further support to cellular senescence
as a feature of NPCs in PPMS and rapamycin as a pharmacological
means to affect the SASP of NPCs.
Of the candidate proteins secreted by PPMS NPCs, we fo-
cused our attention on HMGB1 for several reasons: It is pro-
duced at higher levels in demyelinated lesions in MS brain tissues
(39, 44), it is produced at higher levels by senescent cells (39),
and it has been implicated as a mediator of neuroinflammation
(45). We evaluated HMGB1 gene expression and found signifi-
cantly increased mRNA expression in PPMS NPCs, which was
also down-regulated by rapamycin treatment (Fig. 3C).
We determined whether progenitor cells could be a source of
HMGB1 within demyelinated lesions in human MS brain tissues.
Immunohistochemistry identified a significantly increased pro-
portion of SOX2+/HMGB1+ progenitor cells in demyelinated
white matter lesions compared with NAWM, which decreases in
remyelinated lesions (Fig. 3 D and E). These progenitor cells,
expressing both SOX2 and HMGB1, were further confirmed
using confocal immunofluorescence within the MS lesion tissue
[SI Appendix, Fig. S8 and accompanying Z-stack GIF (Movie
S2)]. These data indicated the presence of elevated cellular se-
nescence in progenitor cells in the PMS brain.
To address the contribution of extracellular HMGB1 to im-
paired OPC differentiation, we repeated the OPC differentiation
experiment using CM from PPMS NPCs but added a well-
characterized function blocking antibody to inhibit HMGB1
(α-HMGB1) or the matched IgG control (Fig. 3F). Maturation
of OLs in the α-HMGB1–treated PPMS CM was significantly
higher compared with OPCs grown in CM with serotype-matched
IgG antisera (control) (Fig. 3G). Blocking HMGB1 was not found
to affect either OLIG2+ cell proliferation or cell death (Fig. 3H). To
test whether extracellular HMGB1 was acting directly as an in-
hibitor of OPC differentiation, we applied recombinant human
HMGB1 (rhHMGB1) to cultures of differentiating OPCs and
measured the proportion of OL maturation (Fig. 3I). Extracellular
rhHMGB1 had a concentration-dependent effect on reducing OPC
differentiation in vitro (Fig. 3J). These data provide direct evidence
that extracellular HMGB1 produced by senescent NPCs can act to
directly suppress OPC maturation.
HMGB1 Mediates Senescence-Related Transcriptomic Changes in
OPCs. To better understand how cellular senescence of NPCs
and their production of extracellular HMGB1 affects the po-
tential for OPCs to mature into MBP+ OLs with myelinating
potential, we performed transcriptomic analyses of OPCs
(Dataset S2). Specifically, we collected cultures of primary OPCs
that had been grown in CM from either PPMS NPCs or non-
disease control NPCs or CM from PPMS NPCs that had been
treated with α-HMGB1 antisera. OPCs were grown for 48 h and
then collected for RNA-seq analyses (Fig. 4A). Genes were fil-
tered for an FDR of <0.05. Substantial transcriptome changes
were seen in the OPCs treated with either control CM, PPMS
CM, or PPMS + α-HMGB1 (Fig. 4 B–D). Of all genes filtered,
Cd99l2 and Wdr54 were found to be the most up-regulated
genes in the OPCs treated with PPMS CM compared with the
OPCs treated with control CM (Fig. 4B). Cd99l2 has been found
to allow for the entrance of leukocytes into the CNS in the ex-
perimental autoimmune encephalomyelitis mouse model of MS.
When knocked out in this disease model, leukocyte entry is
inhibited and disease is ameliorated (46). Treatment of the
PPMS CM with α-HMGB1 did not decrease Wdr54 and
Cd99l2 to levels found in OPCs treated with control CM (Fig.
4C). Treatment of the OPCs with PPMS + α-HMGB1 CM did
increase expression of Map2k3 (Fig. 4B), which was found to be
significantly decreased in OPCs treated with PPMS CM (Fig.
4D). Map2k3, a dual-specificity kinase, has been found to be
associated with a resolution in inflammation (47). Our data
therefore implicate HMGB1 in perpetuating inflammation
in OPCs. Raw sequencing files are available from the National
Center for Biotechnology Information (NCBI) BioProject
(accession no. PRJNA524718).
Our first step in curating these data was to identify differen-
tially expressed genes, which defined several notable ontological
differences between the treatment groups. Senescent cells also
are known to induce senescence through secretion of the SASP
as a paracrine effect, so we examined markers of senescence in
the OPCs. Overall, we found an increase in senescence-
associated genes, such as Mmp2, p16Ink4a (Cdkn2a), and Igfbp2,
when OPCs were treated with PPMS CM, which was reduced
close to normal in PPMS CM containing HMGB1 blocking an-
tibody (Fig. 4E). We also investigated expression of epigenetic
modifiers since epigenetics plays a pivotal role in determining
the potential for OPC differentiation (48). We found that PPMS
CM significantly induced expression of numerous epigenetic
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regulators in OPCs (Fig. 4F). Interestingly, when HMGB1 was
functionally blocked from the PPMS NPC CM, most of these
changes in epigenetic-associated genes were normalized to levels
observed in control NPC CM (Fig. 4F). These RNA-seq data
indicate that the expression and production of HMGB1 by NPCs
play important roles, influencing the potential for OPCs to ma-
ture by modulating gene expression. Moreover, these differences
in senescence-associated and epigenetic modifier genes in OPCs
demonstrate that it is likely locally produced factors from progenitor
cells within demyelinated lesions that contribute to the micro-
environment that determines OPC fate. These observations
provide a compelling link between the presence of senescent
progenitor cells in demyelinated lesions in PMS and ascribe a
deleterious role for cellular senescence in NPCs, which we have
functionally characterized using iPSCs from patients with PPMS.
Discussion
Our data provide a perspective on the pathophysiology of de-
myelinating lesions in MS. We have identified cellular senes-
cence in SOX2+ progenitor cells, which influence, through
paracrine activity, the maturation of OPCs with myelinating
potential. We have also determined that cellular senescence is
potentially reversible or amenable to therapeutic intervention
using rapamycin as a prototypic compound. We used proteo-
mics to determine that senescent NPCs secrete extracellular
HMGB1, which altered gene expression and impaired maturation
of OPCs (Fig. 5). This was also found to be corroborated in human
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Fig. 3. Proteomic analysis of the iPS-derived NPC secretome and characterization of HMGB1 as a directly acting inhibitor of OPC differentiation. (A) Venn
diagram of comparison strategy for proteomic data analysis from control CM, PPMS CM, and PPMS + rapamycin (Rapa) treatment CM. Peptides were
identified by LC-tandem mass spectrometry from each treatment group. The protein threshold was set at 95% confidence of identification. (B) Functional
classification of secreted peptides from PPMS NPCs and nondisease control NPCs as determined by the DAVID bioinformatics database (https://david.ncifcrf.
gov/). Pie graphs depict the proportions of peptides identified associated with disease classifications as determined by Genetic Association Database disease
class. Psych, psychological. (C) Increased HMGB1 mRNA expression in PPMS NPCs was decreased with Rapa treatment [Control (Cntl) vs. PPMS (**P < 0.01), Cntl
vs. PPMS + Rapa (P = 0.4182); ANOVA with Tukey’s multiple comparison test]. Data were normalized to Cntl NPC lines. Each data point represents an in-
dividual stem cell line and/or clone performed in triplicate. ns, not significant. (D) Human tissue staining for SOX2 (blue) and HMGB1 (red) in control and
patients with PMS in the frontal lobe, subcortical white matter. The representative control image is CO 39 (SI Appendix, Table S1), and representative MS
NAWM and MS demyelinated (DM) lesion images are from MS 640 (SI Appendix, Table S1). Arrows point to cells double positive for SOX2 and HMGB1. (Scale
bars, 20 μm.) (E) Increase in percentage of SOX2+ cells expressing HMGB1 in a MS DM lesion compared with MS NAWM (**P < 0.01, two-tailed t test). In-
dividual points are individual patients, and matching colors represent the same patient (SI Appendix, Table S1). Values are mean ± SEM. RM, remyelinated. (F)
Experimental design to test whether functional blocking antisera against HMGB1 (1 μg/mL) in PPMS CM (or IgG control, 1 μg/mL) affected OPC maturation.
rOPCs, rat OPCs. CM from NPCs were collected after 48 h, and α-HMGB1 or IgG control was incubated in CM for 1 h and applied to OPCs. Differentiation (DIFF)
of OPCs was assayed after 48 h. (G) Quantification of OLmaturation from experiment design in F. All conditions are relative to Cntl + IgG, set to 100% [PPMS + IgG vs.
PPMS + α-HMGB1 (****P < 0.0001); ANOVA with Tukey’s multiple comparison test]. All conditions were performed in triplicate with the varying NPC lines. (H)
No significant differences in the number of OLIG2+ cells were observed from the varying treatments on the OPCs (P = 0.7095; ANOVA). (I) Experimental design
to test whether rhHMGB1 affected OPC maturation. Forty-eight hours after treatment of OPCs with varying concentrations of rhHMGB1, DIFF was assayed. (J)
Treatment of OPCs with increasing doses of rhHMGB1 (ng/mL) decreases OL differentiation after 48 h in the presence of differentiation media. All conditions
are relative to PBS, set to 100% [PBS vs. 5,000 ng/mL rhHMGB1 (*P < 0.05); ANOVA with Tukey’s multiple comparison test].
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pathology, demonstrating progenitor cells expressing HMGB1 in
PMS lesions. Age is recognized as a process limiting the myelinating
potential of the CNS (33). Although MS is not typically considered
a disease of aging, because it is generally diagnosed in early-to-
middle adulthood, the functional impact of cellular senescence in
progenitor cells we report here may indicate that premature
cellular aging is an important component of this disease.
Progenitor cells are of particular interest because they have
been found within demyelinated lesions in human tissue as well as
in mouse models of MS (16, 49). Our data suggest that progenitor
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Fig. 4. Transcriptomic analysis of OPCs treated with human NPC CM identifies marked differences in expression of cellular senescence genes (E) and epi-
genetic regulators (F) regulated by HMGB1. (A) OPC RNA was collected after 48 h of treatment with control (Cntl) CM, PPMS CM, or PPMS + α-HMGB1 CM, and
RNA-seq was performed. The image was generated using BioRender. (B–D) Volcano plots of gene expression changes in the OPC transcriptome after
treatment with Cntl CM, PPMS CM, or PPMS + α-HMGB1 CM. The x axis specifies the log of the fold change (logFC), and the y axis specifics the negative
logarithm to the base 10 of the P values. Vertical lines reflect an FC of ±2, and the horizontal line reflects a P value of 0.05. (B) Gene expression changes in Cntl
vs. PPMS CM-treated OPCs. (C) Gene expression changes in Cntl vs. PPMS + α-HMGB1 CM-treated OPCs. (D) Gene expression changes in PPMS vs. PPMS
α-HMGB1 CM-treated OPCs. (E) Heatmap of expression differences in senescence-associated genes in OPCs after treatment with CM. (F) Heatmap of ex-
pression differences in epigenetic-associated genes in OPCs after treatment with CM. Three individual Cntl and PPMS lines were selected and are demon-
strated individually in the heatmaps. RNA was aligned to the latest version of the rat genome (version 6.0.91). The heatmap for each class of genes is as
indicated. Genes with an FDR < 0.05 were sorted by gene ontology using Gene Ontology Consortium and PANTHER (protein analysis through evolutionary
relationships) analysis to get the varying clusters.
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cells in the MS brain are actively contributing to the diminished
regenerative capacity of OPCs within the lesion environment, yet
NPCs are otherwise known to secrete regenerative, antiin-
flammatory, and promyelinating factors, or themselves differenti-
ate into myelinating OLs (17, 50, 51). Currently, there are no
markers that reliably distinguish human NPCs from other resident
progenitor cell populations that could to be used to refine our
identification of the senescent cell types in pathological analyses
(52). Therefore, the senescent SOX2+ progenitor cells we identi-
fied in human brain tissues could represent a continuum of pro-
genitor cells from NPCs to include OPC lineage cells (53, 54). As
our data support, progenitor cells are found in greater numbers
within the lesion area, compared with NAWM and control white
matter, where they can contribute to the regulation of OPC
maturation and myelin regeneration (16). However, our data
would suggest that in PMS, endogenous progenitor cells exhibit
higher levels of senescent markers, and, experimentally, this
phenotype suppresses OPC maturation through the secretion of
factors (the SASP), including HMGB1 (Fig. 5). These findings
contribute to our understanding of the lesion microenvironment
and may explain why immature oligodendroglia within lesions fail
to remyelinate in PMS.
To model SOX2+ progenitor cells found within these lesion
areas in vitro, NPCs were generated from iPSC lines derived
from patients with PPMS (SI Appendix, Table S2). These cells
were found to exhibit equivalent differentiation to an NPC fate,
express identical markers to NPCs from nondisease age-matched
donor iPSC lines (SI Appendix, Fig. S4), and differentiate toward
the OPC lineage in vitro (26); yet, these PPMS NPCs are notable
in their significantly reduced support for OL differentiation (25).
We have now determined that PPMS NPCs display key hall-
marks of cellular senescence, including SA–β-gal staining and
increased p16Ink4a. p16Ink4a is a cyclin-dependent kinase in-
hibitor, a hallmark for identifying senescent cells (55), that plays
a central role in the function of senescent cells (55–61). It acts
through the retinoblastoma pathway, which inhibits the action of
cyclin-dependent kinases (62). Up-regulation of p16Ink4a results
in chromatin reorganization, which leads to changes in genes
related to inflammation and oxidative damage, including COX1 and
COX2 enzymes, as well as other inflammatory mediators (62, 63).
The methylation pattern of p16Ink4a has been proposed to be an
epigenetic risk factor in the development of MS (64). We found that
the expression of p16Ink4a in PPMS NPCs was effectively reduced by
rapamycin, and this was reflected in a functional change in the NPC
secretome evidenced by enhanced OPC maturation after NPC
treatment. Experimental deletion of p16Ink4a-positive cells in mice
has been found to mitigate accelerated aging in models of disease,
including progeria, and, more recently, in glia in a model of Alz-
heimer’s disease (57, 60).
Using both patient iPSCs and the study of human autopsy
tissues, we implicate cellular senescence as a feature of pro-
genitor cells in MS, offering potential for new approaches to
treat this disease. Whether progenitor cells in PMS acquire se-
nescence because of the disease, or a disease treatment (e.g.,
steroids), or are predisposed to developing senescence that then
promotes the disease is presently unclear. It has been shown that
the DNA damage response is strongly linked to senescence in
other cell types where mitochondrial dysfunction has also been
implicated (44). Cells with damaged mitochondria more easily
acquire a senescent phenotype and secrete factors such as
CCL27, TNF-α, and HMGB1 (44). We found HMGB1 only in
CM from PPMS cells, and after treatment with rapamycin,
HMGB1 secretion was abrogated. Extracellular HMGB1 acts as
a cytokine and generates inflammatory responses, such as the
production of additional cytokines and chemokines, continuing
the cycle of chronic inflammation (45). HMGB1 can also be
secreted by activated astrocytes and microglia in lesion areas;
this has been proposed to help recruit NPCs to facilitate repair
(65). However, as our data indicate, if NPCs become senescent
and begin secreting HMGB1, this impairs OPC differentiation,
and thus is deleterious. Our findings demonstrate HMGB1 is a
potent suppressor of OL differentiation. The complexity of hu-
man subjects and the heterogeneity of donor lines in this study
enabled us to refine the list of candidate factors emanating from
PPMS NPCs. However, additional factors on this list, including
XRCC6 and DJ-1, associated with oxidative stress and mito-
chondrial dysfunction, reflect the recapitulation of disease phe-
notype in these iPS-derived cells (66). While these factors were
not addressed specifically in this report, future studies de-
termining their influence on OPCs and myelination would be
expected to provide additional translational understanding to the
impact of the SASP on diminishing remyelination potential
in MS.
Senescence can be induced from natural aging (termed repli-
cative senescence) or can be induced by stressors, including in-
flammation and oxidative stress (44, 67–69). Persistent signs of
oxidative stress and inflammation are associated with de-
myelination, and both are measurable in the brain and in the
blood in PMS (70, 71). The negative impact of senescent cells on
a tissue is mediated through release of factors (the SASP) that
can promote inflammation and disrupt tissue microenvironments
through paracrine activity on surrounding cells (40, 44, 72, 73).
Senescent PPMS NPCs may be affecting other progenitor cells
within the lesion microenvironment by preventing differentiation
through secretion of the SASP. This concept has been termed
the “senescence-stem lock model” (6).
To assess the impact of the PPMS NPC SASP on OPCs, we
performed RNA-seq and identified induction of oxidative stress
markers, epigenetic regulators, and senescence genes. In-
terestingly, genes up-regulated in OPCs treated with PPMS CM
included VCAM1, STAT3, and MYB(AHI1), which had been
previously identified by genome-wide association studies in MS
(74). We identified extracellular HMGB1 as a putative mediator
of transcriptional changes in OPCs linked to their differentiation
potential. Our data show that HMGB1 had a significant negative
impact on the expression of key epigenetic regulators in OPCs,
such as helicase (75, 76) and the histones H2afz, H2afv, and
Fig. 5. Schematic diagram outlining the hypothesized impact of senescent
progenitor cells on remyelinating potential in the MS brain. The recruitment
and presence of senescent progenitor cells in demyelinated white matter
lesions exert a negative impact on the differentiation of OPCs, also within
the demyelinated lesion, by modifying the transcriptional activity of OPCs
via secretion of factors in the SASP, such as HMGB1. Collectively, this model
suggests that cellular senescence in progenitor cells, either acquired as a
result of disease or as a predisposing feature of individuals who develop MS,
contributes to the limited potential of OPCs to foster remyelination in the
MS brain. The image was generated using BioRender.
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H2afx (77). Previous research has implicated HMGB1 as a
modifier of gene promoters and repressors involved in in-
flammation (78). These data support previous studies demon-
strating that epigenetic modifiers are critical determinants of
OPC differentiation potential and remyelination in mouse
models (79–81).
The cause(s) of PMS is not known. Based on these data, we
hypothesize that cellular senescence in progenitor cells impairs
the regenerative potential of the lesion microenvironment. Cur-
rent treatments for MS suppress inflammation and block access of
immune cells into the CNS, yet this does not fully prevent de-
myelination and axonal degeneration (82). Additionally, current
disease-modifying therapies for MS offer limited/no benefit to
patients with PMS (83). The targeting and stimulating of resident
OPCs to differentiate offers important therapeutic potential, but
we speculate that the efficacy of any candidate drug also relies on
overcoming the lesion microenvironment, which would include
addressing the inhibitory influence of senescent progenitor cells.
At present, it is unclear whether cellular senescence is present in
other types of MS, such as relapsing-remitting multiple sclerosis
(RRMS), or what existing therapies may affect cellular senes-
cence. Future studies would be expected to extend the findings
reported herein to address salient questions regarding the impact
of cellular senescence in all forms of MS, including whether vul-
nerability to cellular senescence is a predisposing risk factor to
developing this disease.
In summary, our identification of cellular senescence within
the MS brain provides a mechanism by which aberrant cellular
aging silently subverts natural aging by impairing OPCs and
promoting chronic demyelination. Targeting cellular senes-
cence in progenitor cells, as a means by which to unlock the
differentiation potential of endogenous OPCs, may repre-
sent a novel therapeutic approach to promote remyelination
in MS.
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